Verona Pharma (VRNA) Stock Forecast, Price Target & Predictions
VRNA Stock Forecast
Verona Pharma stock forecast is as follows: an average price target of $33.86 (represents a -10.57% downside from VRNA’s last price of $37.86) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
VRNA Price Target
The average price target for Verona Pharma (VRNA) is $33.86 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $42.00 to $26.00. This represents a potential -10.57% downside from VRNA's last price of $37.86.
VRNA Analyst Ratings
According to 8 Wall Street analysts, Verona Pharma's rating consensus is 'Buy'. The analyst rating breakdown for VRNA stock is 0 'Strong Buy' (0.00%), 8 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Verona Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 05, 2024 | Raghuram Selvaraju | H.C. Wainwright | $42.00 | $38.39 | 9.40% | 10.94% |
| Jul 22, 2024 | Edward Nash | Canaccord Genuity | $37.00 | $22.95 | 61.22% | -2.27% |
| Jun 27, 2024 | Raghuram Selvaraju | H.C. Wainwright | $36.00 | $14.69 | 145.06% | -4.91% |
| May 28, 2024 | Andrew Tsai | Jefferies | $38.00 | $12.50 | 204.00% | 0.37% |
| Apr 16, 2024 | Yasmeen Rahimi | Piper Sandler | $36.00 | $15.80 | 127.85% | -4.91% |
| Dec 21, 2022 | - | H.C. Wainwright | $32.00 | $18.59 | 72.14% | -15.48% |
| Dec 20, 2022 | Andreas Argyrides | Wedbush | $30.00 | $18.05 | 66.20% | -20.76% |
| Dec 20, 2022 | - | Truist Financial | $28.00 | $18.13 | 54.48% | -26.04% |
| Dec 20, 2022 | - | BTIG | $26.00 | $18.14 | 43.29% | -31.33% |
| Aug 30, 2022 | Edward Nash Nash | Canaccord Genuity | $27.00 | $10.25 | 163.41% | -28.68% |
The latest Verona Pharma stock forecast, released on Nov 05, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $42.00, which represents a 9.40% increase from the stock price at the time of the forecast ($38.39), and a 10.94% increase from VRNA last price ($37.86).
Verona Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 5 |
| Avg Price Target | $42.00 | $42.00 | $37.80 |
| Last Closing Price | $37.86 | $37.86 | $37.86 |
| Upside/Downside | 10.94% | 10.94% | -0.16% |
In the current month, the average price target of Verona Pharma stock is $42.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 10.94% increase as opposed to Verona Pharma's last price of $37.86. This month's average price target is down 0.00% compared to last quarter, and up 11.11% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 03, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Oct 03, 2024 | Wells Fargo | - | Overweight | Initialise |
| Sep 12, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 14, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 22, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Jun 27, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 27, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 16, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Dec 20, 2022 | BTIG | Buy | Buy | Hold |
Verona Pharma's last stock rating was published by Piper Sandler on Oct 03, 2024. The company gave VRNA a "Overweight" rating, the same as its previous rate.
Verona Pharma Financial Forecast
Verona Pharma Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $458.00K | - | $40.00M |
| Avg Forecast | $79.01M | $49.99M | $43.47M | $36.22M | $43.90M | $38.37M | $29.86M | $20.89M | $13.15M | $1.51M | $263.34K | $4.08M | $4.52M | $4.63M |
| High Forecast | $114.35M | $72.34M | $62.91M | $52.42M | $63.53M | $55.53M | $43.21M | $31.70M | $17.55M | $1.53M | $381.10K | $5.90M | $4.52M | $4.63M |
| Low Forecast | $56.38M | $35.67M | $31.01M | $25.85M | $31.32M | $27.38M | $21.30M | $14.99M | $9.29M | $1.50M | $187.89K | $2.91M | $4.52M | $4.63M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 3 | 2 | 3 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.11% | - | 8.65% |
Verona Pharma's average Quarter revenue forecast for Jun 24 based on 3 analysts is $263.34K, with a low forecast of $187.89K, and a high forecast of $381.10K. VRNA's average Quarter revenue forecast represents a -42.50% decrease compared to the company's last Quarter revenue of $458.00K (Dec 22).
Verona Pharma EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 3 | 2 | 3 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-12.24M | $-12.06M | $11.43M |
| Avg Forecast | $-15.80M | $-10.00M | $-8.69M | $-7.24M | $-8.78M | $-7.67M | $-5.97M | $-4.18M | $-2.63M | $-302.52K | $-52.67K | $-815.19K | $-903.90K | $-925.22K |
| High Forecast | $-11.28M | $-7.13M | $-6.20M | $-5.17M | $-6.26M | $-5.48M | $-4.26M | $-3.00M | $-1.86M | $-299.35K | $-37.58K | $-581.65K | $-903.90K | $-925.22K |
| Low Forecast | $-22.87M | $-14.47M | $-12.58M | $-10.48M | $-12.71M | $-11.11M | $-8.64M | $-6.34M | $-3.51M | $-305.70K | $-76.22K | $-1.18M | $-903.90K | $-925.22K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 15.01% | 13.35% | -12.35% |
3 analysts predict VRNA's average Quarter EBITDA for Sep 22 to be $-903.90K, with a high of $-903.90K and a low of $-903.90K. This is -107.91% lower than Verona Pharma's previous annual EBITDA (Sep 21) of $11.43M.
Verona Pharma Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 3 | 2 | 3 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-10.45M | $-15.65M | $11.05M |
| Avg Forecast | $2.57M | - | $-642.34K | $-1.28M | $-2.09M | $-2.25M | $-2.73M | $-2.89M | $-3.34M | $-4.14M | $-2.90M | $374.35K | $-878.88K | $-11.53M |
| High Forecast | $4.06M | - | $-403.11K | $-806.21K | $-1.31M | $-1.41M | $-1.71M | $-2.41M | $-2.97M | $-2.60M | $-1.82M | $591.98K | $-878.88K | $-11.53M |
| Low Forecast | $1.61M | - | $-1.02M | $-2.03M | $-3.30M | $-3.56M | $-4.32M | $-3.21M | $-3.71M | $-6.55M | $-4.58M | $234.92K | $-878.88K | $-11.53M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | -27.92% | 17.80% | -0.96% |
Verona Pharma's average Quarter net income forecast for Sep 22 is $-878.88K, with a range of $-878.88K to $-878.88K. VRNA's average Quarter net income forecast represents a -107.95% decrease compared to the company's last Quarter net income of $11.05M (Sep 21).
Verona Pharma SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 3 | 2 | 3 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $8.32M | $5.29M | $10.88M |
| Avg Forecast | $61.42B | $38.86B | $33.79B | $28.16B | $34.12B | $29.83B | $23.21B | $16.24B | $10.22B | $1.18B | $204.70M | $3.17B | $3.51B | $3.60B |
| High Forecast | $88.89B | $56.24B | $48.90B | $40.75B | $49.38B | $43.17B | $33.59B | $24.64B | $13.64B | $1.19B | $296.25M | $4.59B | $3.51B | $3.60B |
| Low Forecast | $43.82B | $27.73B | $24.11B | $20.09B | $24.35B | $21.28B | $16.56B | $11.65B | $7.22B | $1.16B | $146.06M | $2.26B | $3.51B | $3.60B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% |
Verona Pharma's average Quarter SG&A projection for Jun 24 is $204.70M, based on 3 Wall Street analysts, with a range of $146.06M to $296.25M. The forecast indicates a 2359.49% rise compared to VRNA last annual SG&A of $8.32M (Dec 22).
Verona Pharma EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 3 | 2 | 3 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.18 | $-0.23 | $0.16 |
| Avg Forecast | $0.03 | - | $-0.01 | $-0.02 | $-0.03 | $-0.03 | $-0.03 | $-0.04 | $-0.04 | $-0.05 | $-0.04 | - | $-0.01 | $-0.14 |
| High Forecast | $0.05 | - | $-0.00 | $-0.01 | $-0.02 | $-0.02 | $-0.02 | $-0.03 | $-0.04 | $-0.03 | $-0.02 | $0.01 | $-0.01 | $-0.14 |
| Low Forecast | $0.02 | - | $-0.01 | $-0.02 | $-0.04 | $-0.04 | $-0.05 | $-0.04 | $-0.05 | $-0.08 | $-0.06 | - | $-0.01 | $-0.14 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | -39.18% | 21.20% | -1.12% |
According to 3 Wall Street analysts, Verona Pharma's projected average Quarter EPS for Sep 22 is $-0.01, with a low estimate of $-0.01 and a high estimate of $-0.01. This represents a -106.78% decrease compared to VRNA previous annual EPS of $0.16 (Sep 21).
Verona Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $1.73 | $33.86 | 1857.23% | Buy |
| XFOR | X4 Pharmaceuticals | $0.37 | $3.67 | 891.89% | Buy |
| INZY | Inozyme Pharma | $2.69 | $14.67 | 445.35% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.31 | $7.00 | 203.03% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.34 | $38.80 | 190.85% | Buy |
| APLS | Apellis Pharmaceuticals | $27.75 | $74.50 | 168.47% | Buy |
| TERN | Terns Pharmaceuticals | $5.71 | $14.25 | 149.56% | Buy |
| SNDX | Syndax Pharmaceuticals | $15.60 | $34.30 | 119.87% | Buy |
| VKTX | Viking Therapeutics | $51.63 | $102.40 | 98.33% | Buy |
| MREO | Mereo BioPharma Group | $3.68 | $6.75 | 83.42% | Buy |
| IDYA | IDEAYA Biosciences | $26.60 | $46.58 | 75.11% | Buy |
| MLTX | MoonLake Immunotherapeutics | $51.86 | $79.33 | 52.97% | Buy |
| AKRO | Akero Therapeutics | $31.20 | $46.00 | 47.44% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.19 | $6.67 | 28.52% | Buy |
| PTGX | Protagonist Therapeutics | $41.65 | $50.00 | 20.05% | Buy |
| MDGL | Madrigal Pharmaceuticals | $329.24 | $315.75 | -4.10% | Buy |
| VRNA | Verona Pharma | $37.86 | $33.86 | -10.57% | Buy |